The mechanism for glucocorticoid-resistance in a rat hepatoma cell variant that contains functional glucocorticoid receptor.
The mechanism of glucocorticoid resistance has been studied in a rat hepatoma cell variant (6.10.2), which contains low levels of glucocorticoid receptor (GR). These cells seem to have lost all the glucocorticoid-induced transcriptional responses as measured by the lack of induction of expression of stably integrated mouse mammary tumor virus (MMTV) and the endogenous gene tyrosine aminotransferase (TAT), as well as the transcriptional suppression of GR gene expression. Physico-chemical characterization of the GR in the glucocorticoid resistant 6.10.2 cells revealed that the receptor is indistinguishable from the wild-type receptor with regard to size, hormone- and DNA-binding. The levels of the receptor mRNA and the total immunoreactive protein found in 6.10.2 cells were about 20% of those found in wild-type cells. Further analysis of 6.10.2 cells demonstrated that the receptor was indeed biologically functional. Treatment of 6.10.2 cells with 8-bromo-cAMP, which induced the endogenous GR level two-fold, restored responsiveness to glucocorticoids. Secondly, pretreatment of the cells with cycloheximide also led to reacquisition of cellular responsiveness to glucocorticoids. We propose that there exists a "threshold" level of GR, which is required for responsiveness and that under normal culture conditions, the level of GR in 6.10.2 cells is below this threshold. Glucocorticoid responsiveness can be restored by raising the GR level above the threshold with 8-bromo-cAMP or, alternatively, by removing the threshold barrier (repressor protein) with cycloheximide. Finally, the existence of such a repressor protein for MMTV induction was shown by in vivo titration with an isolated negative cis-element from the MMTV promoter.
Okret
S
S
Department of Medical Nutrition, Karolinska Institute, Huddinge University Hospital, Sweden.
Dong
Y
Y
Tanaka
H
H
Cairns
B
B
Gustafsson
J A
JA
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001345:Autoradiography; D001483:Base Sequence; D015152:Blotting, Northern; D015153:Blotting, Western; D002853:Chromatography, Liquid; D003513:Cycloheximide / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005938:Glucocorticoids / Q000378:metabolism*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism*; D008969:Molecular Sequence Data; D010957:Plasmids; D012333:RNA, Messenger / Q000187:drug effects; D012334:RNA, Neoplasm / Q000032:analysis / Q000187:drug effects / Q000302:isolation & purification; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured; D014444:Tyrosine Transaminase / Q000378:metabolism
D005938:Glucocorticoids; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011965:Receptors, Glucocorticoid; D015124:8-Bromo Cyclic Adenosine Monophosphate; D003907:Dexamethasone; D003513:Cycloheximide; D014444:Tyrosine Transaminase